Nurse Practitioner in Suttons Bay, MI Accepting Medicare
5 Nurse Practitioner nurses found. Showing 1 - 5
 Molly Lowe, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 718 N Saint Joseph St Unit K1, Suttons Bay, MI 49682 Phone: 231-386-0088 |
Koleen Rae Kerlin-spigarelli, FNP Nurse Practitioner - Primary Care Medicare: Medicare Enrolled Practice Location: 93 W 4th St, Suttons Bay, MI 49682 Phone: 231-271-5990 |
Shannon Korson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3200 S Center Hwy, Suttons Bay, MI 49682 Phone: 231-590-3437 |
Heather Morgan Sedgwick, FNP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 93 W 4th St Ste B, Suttons Bay, MI 49682 Phone: 231-866-4440 |
Margaret Ann Hall, MSN, RN, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 93 W Fourth St, Suttons Bay, MI 49682 Phone: 231-271-5990 |
News Archive
E-cigarette use may be linked to higher odds of erectile dysfunction regardless of smoking history
Smoking has long been associated with Erectile Dysfunction (ED) and Cardiovascular Disease (CVD). However, little research has explored if there is a similar association among men who use Electronic Nicotine Delivery Systems (ENDS), commonly referred to as e-cigarettes.
Anulex Technologies announces the commercial availability of Xclose Plus Tissue Repair System
Anulex Technologies, Inc., a privately held medical device manufacturer focusing on spinal disc Preservation & Anular Repair™ products, announced the commercial availability of the Xclose™ Plus Tissue Repair System at the AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves meeting in Orlando, Florida.
Key prostaglandin metabolic enzyme shows promise as drug target for tissue regeneration
A new study co-led by Hsin-Hsiung Tai, professor of pharmaceutical sciences at the University of Kentucky, suggests that a key prostaglandin (PG) metabolic enzyme shows promise as a drug target to help tissue regeneration and repair, particularly after bone marrow transplantation and tissue injuries.
Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer.
› Verified 1 days ago